Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase

Nucleic Acids Research

Volumn 40, Issue 1, 2012, Pages 345-359

  Ndongwe, Tanyaradzwa P ^a   Adedeji, Adeyemi O ^a   Michailidis, Eleftherios ^a   Ong, Yee Tsuey ^a   Hachiya, Atsuko ^a   Marchand, Bruno ^a   Ryan, Emily M ^a   Rai, Devendra K ^a   Kirby, Karen A ^a   Whatley, Angela S ^a   Burke, Donald H ^a   Johnson, Marc ^a   Ding, Shilei ^b   Zheng, Yi Min ^a   Liu, Shan Lu ^a,b   Kodama, Ei Ichi ^c   Delviks Frankenberry, Krista A ^d   Pathak, Vinay K ^d   Mitsuya, Hiroaki ^e,f   Parniak, Michael A ^g   Singh, Kamalendra ^a   Sarafianos, Stefan G ^a   more..

^a University of Missouri   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER INSTITUTE   (United States)

^e KUMAMOTO UNIVERSITY   (Japan)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; APTAMER; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA APTAMER; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIRUS DNA; ZIDOVUDINE;

AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CONTROLLED STUDY; DISSOCIATION; DNA SYNTHESIS; ENZYME ANALYSIS; ENZYME CHEMISTRY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME SPECIFICITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STEADY STATE; SURFACE PLASMON RESONANCE; VIRUS MUTANT; VIRUS RESISTANCE; XENOTROPIC MULV RELATED VIRUS;

ADENINE; AMINO ACID SEQUENCE; APTAMERS, NUCLEOTIDE; BETA-GALACTOSIDASE; DNA; HIV REVERSE TRANSCRIPTASE; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLONEY MURINE LEUKEMIA VIRUS; MUTATION; NUCLEOTIDES; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SEQUENCE HOMOLOGY, AMINO ACID; XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS; ZIDOVUDINE;

GAMMARETROVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; XENOTROPIC MURINE LEUKEMIA VIRUS;

EID: 84855281969     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkr694     Document Type: Article

References (85)

1. Urisman, A., Molinaro, R.J., Fischer, N., Plummer, S.J., Casey, G., Klein, E.A., Malathi, K., Magi-Galluzzi, C., Tubbs, R.R., Ganem, D. et al. (2006) Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog., 2, e25.
2. Malathi, K., Dong, B., Gale, M. Jr. and Silverman, R.H. (2007) Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature, 448, 816-819. (Pubitemid 47266340)
3. Arnold, R.S., Makarova, N.V., Osunkoya, A.O., Suppiah, S., Scott, T.A., Johnson, N.A., Bhosle, S.M., Liotta, D., Hunter, E., Marshall, F.F. et al. XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology, 75, 755-761.
4. Dong, B., Kim, S., Hong, S., Das Gupta, J., Malathi, K., Klein, E.A., Ganem, D., Derisi, J.L., Chow, S.A. and Silverman, R.H. (2007) An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci. USA, 104, 1655-1660. (Pubitemid 46214646)
5. Knouf, E.C., Metzger, M.J., Mitchell, P.S., Arroyo, J.D., Chevillet, J.R., Tewari, M. and Miller, A.D. (2009) Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells. J. Virol., 83, 7353-7356.
6. Schlaberg, R., Choe, D.J., Brown, K.R., Thaker, H.M. and Singh, I.R. (2009) XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc. Natl Acad. Sci. USA, 106, 16351-16356.
7. Sabunciyan, S., Mandelberg, N., Rabkin, C.S., Yolken, R. and Viscidi, R. No difference in antibody titers against xenotropic MLV related virus in prostate cancer cases and cancer-free controls. Mol. Cell. Probes., 25, 134-136.
8. Verhaegh, G.W., de Jong, A.S., Smit, F.P., Jannink, S.A., Melchers, W.J. and Schalken, J.A. (2011) Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients. Prostate, 71, 415-420.
9. Hohn, O., Krause, H., Barbarotto, P., Niederstadt, L., Beimforde, N., Denner, J., Miller, K., Kurth, R. and Bannert, N. (2009) Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology, 6, 92.
10. Lombardi, V.C., Ruscetti, F.W., Das Gupta, J., Pfost, M.A., Hagen, K.S., Peterson, D.L., Ruscetti, S.K., Bagni, R.K., Petrow-Sadowski, C., Gold, B. et al. (2009) Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science, 326, 585-589.
11. Henrich, T.J., Li, J.Z., Felsenstein, D., Kotton, C.N., Plenge, R.M., Pereyra, F., Marty, F.M., Lin, N.H., Grazioso, P., Crochiere, D.M. et al. (2010) Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J. Infect. Dis., 202, 1478-1481.
12. Erlwein, O., Kaye, S., McClure, M.O., Weber, J., Wills, G., Collier, D., Wessely, S. and Cleare, A. (2010) Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS ONE, 5, e8519.
13. Groom, H.C., Boucherit, V.C., Makinson, K., Randal, E., Baptista, S., Hagan, S., Gow, J.W., Mattes, F.M., Breuer, J., Kerr, J.R. et al. (2010) Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology, 7, 10.
14. Switzer, W.M., Jia, H., Hohn, O., Zheng, H., Tang, S., Shankar, A., Bannert, N., Simmons, G., Hendry, R.M., Falkenberg, V.R. et al. (2010) Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology, 7, 57.
15. Satterfield, B.C., Garcia, R.A., Jia, H., Tang, S., Zheng, H. and Switzer, W.M. (2011) Serologic and PCR testing of persons with chronic fatigue syndrome in the United States shows no association with xenotropic or polytropic murine leukemia virus-related viruses. Retrovirology, 8, 12.
16. Menendez-Arias, L. Evidence and controversies on the role of XMRV in prostate cancer and chronic fatigue syndrome. Rev. Med. Virol., 21, 3-17.
17. Hue, S., Gray, E.R., Gall, A., Katzourakis, A., Tan, C.P., Houldcroft, C.J., McLaren, S., Pillay, D., Futreal, A., Garson, J.A. et al. (2010) Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology, 7, 111.
18. Paprotka, T., Delviks-Frankenberry, K.A., Cingoz, O., Martinez, A., Kung, H.J., Tepper, C.G., Hu, W.S., Fivash, M.J. Jr., Coffin, J.M. and Pathak, V.K. (2011) Recombinant origin of the retrovirus XMRV. Science, 333, 97-101.
19. Singh, K., Kaushik, N., Jin, J., Madhusudanan, M. and Modak, M.J. (2000) Role of Q190 of MuLV RT in ddNTP resistance and fidelity of DNA synthesis: a molecular model of interactions with substrates. Protein Eng., 13, 635-643.
20. Telesnitsky, A. and Goff, S.P. (1993) Two defective forms of reverse transcriptase can complement to restore retroviral infectivity. EMBO J., 12, 4433-4438. (Pubitemid 23302058)
21. Georgiadis, M.M., Jessen, S.M., Ogata, C.M., Telesnitsky, A., Goff, S.P. and Hendrickson, W.A. (1995) Mechanistic implications from the structure of a catalytic fragment of Moloney murine leukemia virus reverse transcriptase. Structure, 3, 879-892.
22. Das, D. and Georgiadis, M.M. (2004) The crystal structure of the monomeric reverse transcriptase from Moloney murine leukemia virus. Structure, 12, 819-829. (Pubitemid 38595770)
23. Chowdhury, K., Kaushik, N., Pandey, V.N. and Modak, M.J. (1996) Elucidation of the role of Arg 110 of murine leukemia virus reverse transcriptase in the catalytic mechanism: biochemical characterization of its mutant enzymes. Biochemistry, 35, 16610-16620. (Pubitemid 27020504)
24. Kaushik, N., Chowdhury, K., Pandey, V.N. and Modak, M.J. (2000) Valine of the YVDD motif of moloney murine leukemia virus reverse transcriptase: role in the fidelity of DNA synthesis. Biochemistry, 39, 5155-5165. (Pubitemid 30241638)
25. Jacobo-Molina, A., Ding, J., Nanni, R.G., Clark, A.D. Jr., Lu, X., Tantillo, C., Williams, R.L., Kamer, G., Ferris, A.L., Clark, P. et al. (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc. Natl Acad. Sci. USA, 90, 6320-6324. (Pubitemid 23191507)
26. Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A. and Steitz, T.A. (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 256, 1783-1790.
27. Sarafianos, S.G., Marchand, B., Das, K., Himmel, D.M., Parniak, M.A., Hughes, S.H. and Arnold, E. (2009) Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol., 385, 693-713.
28. Singh, K., Marchand, B., Kirby, K.A., Michailidis, E. and Sarafianos, S.G. (2010) Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase. Viruses, 2, 606-638.
29. Schuckmann, M.M., Marchand, B., Hachiya, A., Kodama, E.N., Kirby, K.A., Singh, K. and Sarafianos, S.G. (2010) The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine. J. Biol. Chem., 285, 38700-38709.
30. Telesnitsky, A. and Goff, S.P. (1993) RNase H domain mutations affect the interaction between Moloney murine leukemia virus reverse transcriptase and its primer-template. Proc. Natl Acad. Sci. USA, 90, 1276-1280. (Pubitemid 23058154)
31. Bauman, J.D., Das, K., Ho, W.C., Baweja, M., Himmel, D.M., Clark, A.D. Jr., Oren, D.A., Boyer, P.L., Hughes, S.H., Shatkin, A.J. et al. (2008) Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design. Nucleic Acids Res., 36, 5083-5092.
32. Michailidis, E., Marchand, B., Kodama, E.N., Singh, K., Matsuoka, M., Kirby, K.A., Ryan, E.M., Sawani, A.M., Nagy, E., Ashida, N. et al. (2009) Mechanism of inhibition of HIV-1 reverse transcriptase by 40-Ethynyl-2-fluoro- 20-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J. Biol. Chem., 284, 35681-35691.
33. Meyer, P.R., Matsuura, S.E., So, A.G. and Scott, W.A. (1998) Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl Acad. Sci. USA, 95, 13471-13476. (Pubitemid 28522996)
34. Halvas, E.K., Svarovskaia, E.S. and Pathak, V.K. (2000) Development of an in vivo assay to identify structural determinants in murine leukemia virus reverse transcriptase important for fidelity. J Virol, 74, 312-319. (Pubitemid 30002911)
35. Patel, S.S., Wong, I. and Johnson, K.A. (1991) Pre-steady-state kinetic analysis of processive DNA replication including complete characterization of an exonuclease-deficient mutant. Biochemistry, 30, 511-525.
36. Sarafianos, S.G., Clark, A.D. Jr., Das, K., Tuske, S., Birktoft, J.J., Ilankumaran, P., Ramesha, A.R., Sayer, J.M., Jerina, D.M., Boyer, P.L. et al. (2002) Structures of HIV-1 reverse transcriptase with pre-and post-translocation AZTMP-terminated DNA. EMBO J., 21, 6614-6624. (Pubitemid 35448438)
37. Tuske, S., Sarafianos, S.G., Clark, A.D. Jr., Ding, J., Naeger, L.K., White, K.L., Miller, M.D., Gibbs, C.S., Boyer, P.L., Clark, P. et al. (2004) Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat. Struct. Mol. Biol., 11, 469-474. (Pubitemid 38568952)
38. Sarafianos, S.G., Pandey, V.N., Kaushik, N. and Modak, M.J. (1995) Site-directed mutagenesis of arginine 72 of HIV-1 reverse transcriptase. Catalytic role and inhibitor sensitivity. J. Biol. Chem., 270, 19729-19735.
39. Hachiya, A., Kodama, E.N., Schuckmann, M.M., Kirby, K.A., Michailidis, E., Sakagami, Y., Oka, S., Singh, K. and Sarafianos, S.G. (2011) K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism. PLoS One, 6, e16242.
40. Sarafianos, S.G., Das, K., Ding, J., Boyer, P.L., Hughes, S.H. and Arnold, E. (1999) Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem. Biol., 6, R137-R146. (Pubitemid 29363176)
41. Boyer, P.L., Sarafianos, S.G., Clark, P.K., Arnold, E. and Hughes, S.H. (2006) Why do HIV-1 and HIV-2 use different pathways to develop AZT resistancé PLoS Pathog., 2, e10.
42. Powell, M.D., Ghosh, M., Jacques, P.S., Howard, K.J., Le Grice, S.F. and Levin, J.G. (1997) Alanine-scanning mutations in the "primer grip" of p66 HIV-1 reverse transcriptase result in selective loss of RNA priming activity. J. Biol. Chem., 272, 13262-13269. (Pubitemid 27216755)
43. Sarafianos, S.G., Das, K., Clark, A.D. Jr., Ding, J., Boyer, P.L., Hughes, S.H. and Arnold, E. (1999) Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl Acad. Sci. USA, 96, 10027-10032. (Pubitemid 29422506)
44. Boucher, C.A., Cammack, N., Schipper, P., Schuurman, R., Rouse, P., Wainberg, M.A. and Cameron, J.M. (1993) High-level resistance to (-) enantiomeric 20-deoxy-30-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother., 37, 2231-2234. (Pubitemid 23298217)
45. Tisdale, M., Kemp, S.D., Parry, N.R. and Larder, B.A. (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 30-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl Acad. Sci. USA, 90, 5653-5656. (Pubitemid 23176219)
46. Menendez-Arias, L. (2010) Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res., 85, 210-231.
47. Sarafianos, S.G., Das, K., Hughes, S.H. and Arnold, E. (2004) Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr. Opin. Struct. Biol., 14, 716-730. (Pubitemid 39592583)
48. Menendez-Arias, L. (2010) Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res., 85, 210-231.
49. Menendez-Arias, L. and Berkhout, B. (2008) Retroviral reverse transcription. Virus Res., 134, 1-3.
50. Shi, Q., Singh, K., Srivastava, A., Kaushik, N. and Modak, M.J. (2002) Lysine 152 of MuLV reverse transcriptase is required for the integrity of the active site. Biochemistry, 41, 14831-14842. (Pubitemid 35470661)
51. Johnson, K.A. (1993) Conformational coupling in DNA polymerase fidelity. Annu. Rev. Biochem., 62, 685-713. (Pubitemid 23237885)
52. Rezende, L.F. and Prasad, V.R. (2004) Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates. Int. J. Biochem. Cell Biol., 36, 1716-1734. (Pubitemid 38750242)
53. Paprotka, T., Venkatachari, N.J., Chaipan, C., Burdick, R., Delviks-Frankenberry, K.A., Hu, W.S. and Pathak, V.K. Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J. Virol., 84, 5719-5729.
54. Sakuma, R., Sakuma, T., Ohmine, S., Silverman, R.H. and Ikeda, Y. (2010) Xenotropic murine leukemia virus-related virus is susceptible to AZT. Virology, 397, 1-6.
55. Singh, I.R., Gorzynski, J.E., Drobysheva, D., Bassit, L. and Schinazi, R.F. (2010) Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One, 5, e9948.
56. Smith, R.A., Gottlieb, G.S. and Miller, A.D. (2010) Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors. Retrovirology, 7, 70.
57. Kawamoto, A., Kodama, E., Sarafianos, S.G., Sakagami, Y., Kohgo, S., Kitano, K., Ashida, N., Iwai, Y., Hayakawa, H., Nakata, H. et al. (2008) 20-deoxy-40-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int. J. Biochem. Cell Biol., 40, 2410-2420.
58. Kodama, E.I., Kohgo, S., Kitano, K., Machida, H., Gatanaga, H., Shigeta, S., Matsuoka, M., Ohrui, H. and Mitsuya, H. (2001) 40-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob. Agents Chemother., 45, 1539-1546. (Pubitemid 32374131)
59. Kissel, J.D., Held, D.M., Hardy, R.W. and Burke, D.H. (2007) Single-stranded DNA aptamer RT1t49 inhibits RT polymerase and RNase H functions of HIV type 1, HIV type 2, and SIVCPZ RTs. AIDS Res. Hum. Retroviruses., 23, 699-708. (Pubitemid 46867468)
60. Chen, H. and Gold, L. (1994) Selection of high-affinity RNA ligands to reverse transcriptase: inhibition of cDNA synthesis and RNase H activity. Biochemistry, 33, 8746-8756. (Pubitemid 24255068)
61. Joshi, P.J., Fisher, T.S. and Prasad, V.R. (2003) Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals. Curr. Drug Targets Infect. Disord., 3, 383-400. (Pubitemid 38016625)
62. DeStefano, J.J. and Nair, G.R. (2008) Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase. Oligonucleotides, 18, 133-144. (Pubitemid 352019747)
63. DeStefano, J.J. and Cristofaro, J.V. (2006) Selection of primer-template sequences that bind human immunodeficiency virus reverse transcriptase with high affinity. Nucleic Acids Res., 34, 130-139. (Pubitemid 43160039)
64. Arion, D., Kaushik, N., McCormick, S., Borkow, G. and Parniak, M.A. (1998) Phenotypic mechanism of HIV-1 resistance to 30-azido-30-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry, 37, 15908-15917. (Pubitemid 28524762)
65. Sarafianos, S.G., Hughes, S.H. and Arnold, E. (2004) Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs. Int. J. Biochem. Cell Biol., 36, 1706-1715. (Pubitemid 38748529)
66. Shafer, R.W., Kozal, M.J., Winters, M.A., Iversen, A.K., Katzenstein, D.A., Ragni, M.V., Meyer, W.A. 3rd, Gupta, P., Rasheed, S., Coombs, R. et al. (1994) Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis., 169, 722-729.
67. Shirasaka, T., Kavlick, M.F., Ueno, T., Gao, W.Y., Kojima, E., Alcaide, M.L., Chokekijchai, S., Roy, B.M., Arnold, E., Yarchoan, R. et al. (1995) Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl Acad. Sci. USA, 92, 2398-2402.
68. Iversen, A.K., Shafer, R.W., Wehrly, K., Winters, M.A., Mullins, J.I., Chesebro, B. and Merigan, T.C. (1996) Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol., 70, 1086-1090. (Pubitemid 26029028)
69. Winters, M.A., Shafer, R.W., Jellinger, R.A., Mamtora, G., Gingeras, T. and Merigan, T.C. (1997) Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob. Agents Chemother., 41, 757-762. (Pubitemid 27150526)
70. Gu, Z., Gao, Q., Fang, H., Salomon, H., Parniak, M.A., Goldberg, E., Cameron, J. and Wainberg, M.A. (1994) Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 20, 30-dideoxycytidine and 20, 30-dideoxy-30-thiacytidine. Antimicrob. Agents Chemother., 38, 275-281. (Pubitemid 24054247)
71. Knox, K., Carrigan, D., Simmons, G., Teque, F., Zhou, Y., Hackett, J. Jr., Qiu, X., Luk, K.C., Schochetman, G., Knox, A. et al. (2011) No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science.
72. Oakes, B., Tai, A.K., Cingoz, O., Henefield, M.H., Levine, S., Coffin, J.M. and Huber, B.T. (2010) Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences. Retrovirology, 7, 109.
73. Robinson, M.J., Erlwein, O.W., Kaye, S., Weber, J., Cingoz, O., Patel, A., Walker, M.M., Kim, W.J., Uiprasertkul, M., Coffin, J.M. et al. (2010) Mouse DNA contamination in human tissue tested for XMRV. Retrovirology, 7, 108.
74. Sato, E., Furuta, R.A. and Miyazawa, T. (2010) An endogenous murine leukemia viral genome contaminant in a commercial RT-PCR kit is amplified using standard primers for XMRV. Retrovirology, 7, 110.
75. Coffin, J.M. and Stoye, J.P. (2009) Virology. A new virus for old diseases? Science, 326, 530-531.
76. Huang, H., Chopra, R., Verdine, G.L. and Harrison, S.C. (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science, 282, 1669-1675. (Pubitemid 28549275)
77. Sarafianos, S.G., Das, K., Tantillo, C., Clark, A.D. Jr., Ding, J., Whitcomb, J.M., Boyer, P.L., Hughes, S.H. and Arnold, E. (2001) Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J., 20, 1449-1461. (Pubitemid 32233984)
78. Kirby, K.A., Singh, K., Michailidis, E., Marchand, B., Kodama, E.N., Ashida, N., Mitsuya, H., Parniak, M.A. and Sarafianos, S.G. The sugar ring conformation of 40-ethynyl-2-fluoro-20-deoxyadenosine and its recognition by the polymerase active site of hiv reverse transcriptase. Cell Mol. Biol., 57, 40-46.
79. Gotte, M., Arion, D., Parniak, M.A. and Wainberg, M.A. (2000) The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol., 74, 3579-3585. (Pubitemid 30180301)
80. Wainberg, M.A., Drosopoulos, W.C., Salomon, H., Hsu, M., Borkow, G., Parniak, M., Gu, Z., Song, Q., Manne, J., Islam, S. et al. (1996) Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science, 271, 1282-1285. (Pubitemid 26082649)
81. Pandey, V.N., Kaushik, N., Rege, N., Sarafianos, S.G., Yadav, P.N. and Modak, M.J. (1996) Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry, 35, 2168-2179. (Pubitemid 26071650)
82. Das, K., Bandwar, R.P., White, K.L., Feng, J.Y., Sarafianos, S.G., Tuske, S., Tu, X., Clark, A.D. Jr., Boyer, P.L., Hou, X. et al. (2009) Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J. Biol. Chem., 284, 35092-35100.
83. Meyer, P.R., Matsuura, S.E., Mian, A.M., So, A.G. and Scott, W.A. (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell., 4, 35-43. (Pubitemid 29386129)
84. Ueno, T., Shirasaka, T. and Mitsuya, H. (1995) Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 20, 30-dideoxynucleoside 50-triphosphates. J. Biol. Chem., 270, 23605-23611.
85. Rhee, S.Y., Gonzales, M.J., Kantor, R., Betts, B.J., Ravela, J. and Shafer, R.W. (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res., 31, 298-303. (Pubitemid 36150389)